The first patient in the phase 2 Multiple Myeloma study was dosed and an IND submission to FDA is planned for MP0250 in EGFR-mutated Non-Small Cell Lung Cancer (EGFR mut NSCLC) in H2 2017.
Monthly Archives: May 2017
The Board of Directors of Molecular Partners has unanimously appointed Patrick Amstutz, Ph.D. and co-founder of the company, as Chief Executive Officer and decided to nominate him to become a member of the Board of Directors.
At the AGM of Molecular Partners, the shareholders of the company approved all motions proposed by the Board of Directors with a large majority and elected Gwen Fyfe as new member of the Board.
Molecular Partners’ strategic partner Allergan has completed the patient recruitment in the two global AMD Phase 3 studies of abicipar pegol.
Molecular Partners announced its Quarterly Management Statement and key financial highlights for Q1 2017.